Invitation to audiocast for Devyser’s Q3 report 2023
On Thursday November 9, at 09:00 CET, Devyser Diagnostics AB will host an online presentation of its Q3 2023 report (which will have been published earlier on November 9, at 07.30 CET). The presentation will be held in English.
Dial-in number to the teleconference and a conference ID will be received by registering on the link below:
https://conference.financialhearings.com/teleconference/?id=5003819
The presentation will also be webcast and can be accessed from the following web address:
https://ir.financialhearings.com/devyser-diagnostics-q3-report-2023
Speakers: CEO Fredrik Alpsten and CFO Sabina Berlin
The information was submitted for publication, through the agency of the contact persons below, on October 30, 2023, at 08:00 CET.
For more information, please contact:
Fredrik Alpsten, CEO
E-mail: fredrik.alpsten@devyser.com
Tel: +46 706 67 3106
Sabina Berlin, CFO
E-mail: sabina.berlin@devyser.com
Tel: +46 739 519 502
About Devyser
Devyser develops, manufactures, and sells diagnostic solutions and analysis services to clinical laboratories in more than 50 countries. Our products are used for advanced genetic testing in the hereditary disease, oncology, and transplant fields, to enable targeted cancer treatment, the diagnosis of many genetic diseases, and transplant patient follow-up. Devyser’s products, and unique, patented solution requiring only one test tube, simplify genetic testing processes, improve sample throughput, minimize hands-on time, and deliver rapid results. Our goal is for every patient to receive a correct diagnosis in the shortest possible time. Sustainability is a central part of Devyser’s business model, which is a prerequisite for long term value creation.
Devyser was founded in 2004 and is based in Stockholm, Sweden. The company has eight in-house sales offices in Europe and the US, and a CLIA certified laboratory in Atlanta, Georgia. In August 2022, Devyser's quality management system was certified according to the IVDR.
Devyser’s shares are listed on the Nasdaq First North Premier Growth Market Stockholm (ticker: DVYSR). The company’s Certified Adviser is Redeye AB.
For more information, visit www.devyser.com.